{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:27:33Z","timestamp":1791329253073,"version":"4.3.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.ygyno.2007.08.062","type":"journal-article","created":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T17:16:46Z","timestamp":1190999806000},"page":"53-57","source":"Crossref","is-referenced-by-count":31,"title":["Weekly topotecan for recurrent platinum resistant ovarian cancer"],"prefix":"10.1016","volume":"108","author":[{"given":"Fadi","family":"Abushahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diljeet K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Lurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Grendys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred W.","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian C.","family":"Schink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2007.08.062_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management strategies for a chronic disease","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2007.08.062_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0090-8258(89)90175-3","article-title":"Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma","volume":"34","author":"Hoskins","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2.trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2007.08.062_bib4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum and paclitaxel resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib6","first-page":"S5-19-25","article-title":"Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma","volume":"24","author":"ten Bokkel Huinink","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib7","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib8","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/gyno.2001.6435","article-title":"A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients","volume":"83","author":"Homesley","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ygyno.2004.08.026","article-title":"Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer","volume":"95","author":"Bhoola","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2004.09.005","article-title":"Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer","volume":"95","author":"Levy","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ygyno.2005.04.032","article-title":"Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma","volume":"98","author":"O'Malley","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib14","article-title":"Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer","volume":"vol. 5058","author":"Morris","year":"2005"},{"key":"10.1016\/j.ygyno.2007.08.062_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2007.08.062_bib16","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib17","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1634\/theoncologist.7-5-437","article-title":"Ca 125 response: can it replace the traditional response criteria in ovarian cancer?","volume":"7","author":"Guppy","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2007.08.062_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1634\/theoncologist.7-suppl_5-29","article-title":"Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer","volume":"7","author":"Morris","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2007.08.062_bib20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1634\/theoncologist.7-4-324","article-title":"Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?","volume":"7","author":"Rowinsky","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2007.08.062_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/gyno.2002.6811","article-title":"A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients","volume":"87","author":"Homesley","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2007.08.062_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.9-1-33","article-title":"Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity","volume":"9","author":"Armstrong","year":"2004","journal-title":"Oncologist"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807006518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807006518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T11:16:02Z","timestamp":1556882162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825807006518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0090825807006518"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2007.08.062","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}